Functional scintigraphy of the adrenal gland
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Over the last 30 years nuclear medicine imaging of the adrenal gland and its lesions has been achieved by the exploitation of a number of physiological characteristics of this organ. By seeking and utilising features which are quantitatively or qualitatively different from those of the adjacent tissues, functional depiction of the adrenal gland and its diseases, which in most cases retain the basic physiology of their tissue of origin, including both the cortex and the medulla, are now a useful clinical reality. Agents widely used in clinical practice include: (a) uptake and storage of radiolabelled cholesterol analogues via the low density lipoprotein (LDL) receptor and cholesterol ester storage pool in the adrenal cortex ((131)I-6-beta-iodomethyl-norcholesterol, (75)Se-selenomethyl-norcholesterol); (b) catecholamine type I, presynaptic, uptake mechanism and intracellular granule uptake and storage mechanism in the adrenal medulla and extra-adrenal paraganglia ((131)I-, (123)I- and (124)I-meta-iodo-benzyl-guanidine (MIBG), (18)F-metafluoro-benzyl-guanidine); (c) cell surface receptor binding of peptides/neurotransmitters/modulators such as for the family of five subtypes of somatostatin receptors ((123)I-tyr-octreotide, (111)In-DTPA-octreotide, (111)In-DOTA-octreotide and many others); (d) although not specific for the adrenal gland, increased glycolysis by tumours, particularly the most malignant varieties, (18)F-2-fluoro-d-deoxyglucose can thus be expected to depict certain malignant lesions such as malignant pheochromocytomas (particularly the minority which are not detected by MIBG) and adrenal incidentalomas (particularly when they occur in patients with known extra-adrenal malignancies). There are a variety of adrenal tissue characteristics with potential for exploitation but which are not currently in clinical use, and which may, nevertheless, have potential as imaging agents. These include: (a) inhibitors of adrenal cortical steroid hormone synthesis enzymes (e.g. radiolabelled analogues of metyrapone); (b) radiolabelled lipoproteins which bind to adrenocortical LDL receptors; (c) inhibitors of catecholamine biosynthesis enzymes (e.g. radiolabelled analogues of tyrosine and related amino acids); (d) cell surface receptors for various peptides and hormones which may be over-expressed on adrenal cortical or adrenal medullary tumours (e.g. radiolabelled analogues of ACTH on adrenocortical cells of zona fasciculata or zona glomerulosa origin, neurotransmitter/hormone message peptides binding to cell surface receptors such as bombesin, vasoactive intestinal polypeptide, cholecystokinin and opiate peptides); (e) the adrenal cortex can also synthesise cholesterol ab initio from acetate, and preliminary studies with (11)C-acetate positron emission tomography have shown interesting results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonfunctioning adrenal masses: incidental discovery on computed tomography
Glazer, H., Weyman, P., Sagel, S., Levitt, R., & McClennan, B. (1982) · American Journal of Roentgenology · doi:10.2214/ajr.139.1.81 · Cited by 347
Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions
Maurea, S., Mainolfi, C., Bazzicalupo, L., Panico, M. R., Imparato, C., Alfano, B., Ziviello, M., & Salvatore, M. (1999) · American Journal of Roentgenology · doi:10.2214/ajr.173.1.10397094 · Cited by 159
Cited by
The clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781
“For the localization and identification of pheochromocytomas and other sympathomedullary diseases, the radiopharmaceuticals (123)I-MIBG and (131)I-MIBG and (111)In-octreotide have been most commonly used (252).”
BackgroundMethodAME Position Statement on adrenal incidentaloma
Terzolo, M., Stigliano, A., Chiodini, I., Loli, P., Furlani, L., Arnaldi, G., Reimondo, G., Pia, A., Toscano, V, Zini, M., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1147 · Cited by 520
131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging
Bombardieri, E., Giammarile, F., Aktolun, C., Baum, R. P., Bischof Delaloye, A., Maffioli, L., Moncayo, R., Mortelmans, L., Pepe, G., Reske, S. N., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1545-7 · Cited by 305
Burton, T. J., Mackenzie, I. S., Balan, K., Koo, B., Bird, N., Soloviev, D. V., Azizan, E. A. B., Aigbirhio, F., Gurnell, M., & Brown, M. J. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1537 · Cited by 226
Avram, A. M., Fig, L. M., & Gross, M. D. (2006) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2006.03.004 · Cited by 66
Self-citation
Metadata
- Authors
- Rubello, D., Bui, C., Casara, D., Gross, M., Fig, L., & Shapiro, B.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-07-01
- Volume
- 147
- Issue
- 1
- Pages
- 13-28
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2167131903
- Cited by
- 92
- References
- 2
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.